Singapore-based Tessa Therapeutics has shared clinical data from the pilot stage of an ongoing Phase 2 study of TT11, an autologous CD30 chimeric antigen receptor T-cell (CAR-T) therapy. The data found that the CAR-T therapy had a favorable safety profile and promising efficacy in relapsed or refractory CD30-positive classical Hodgkin lymphoma (cHL) patients. Recipients of…